Seismic Therapeutic has successfully dosed the first cohort of healthy participants in Phase I clinical trials for both S-4321 and S-1117, marking significant progress in the company's immunology pipeline.
Seismic Therapeutic has dosed the first cohort of healthy participants in a Phase 1 trial of S-1117, a novel pan-IgG protease designed to target autoantibodies in multiple autoimmune conditions.
Drug Development Updates
Stay informed with timely notifications on clinical trials and research advancements.